Visnadine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412346

CAS#: 477-32-7

Description: Visnadine is a natural vasodilator. It was first isolated from bishop's weed, a plant indigenous to the Mediterranean region which has been used for centuries in Egypt as a spasmolytic.

Chemical Structure

img
Visnadine
CAS# 477-32-7
Instruction

Theoretical Analysis

MedKoo Cat#: 412346
Name: Visnadine
CAS#: 477-32-7
Chemical Formula: C21H24O7
Exact Mass: 388.15
Molecular Weight: 388.420
Elemental Analysis: C, 64.94; H, 6.23; O, 28.83

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Visnadine; BRN0055264; BRN-0055264; BRN 0055264

IUPAC/Chemical Name: (9R,10R)-10-acetoxy-8,8-dimethyl-2-oxo-9,10-dihydro-2H,8H-pyrano[2,3-f]chromen-9-yl (R)-2-methylbutanoate

InChi Key: GVBNSPFBYXGREE-CXWAGAITSA-N

InChi Code: InChI=1S/C21H24O7/c1-6-11(2)20(24)27-19-18(25-12(3)22)16-14(28-21(19,4)5)9-7-13-8-10-15(23)26-17(13)16/h7-11,18-19H,6H2,1-5H3/t11-,18-,19-/m1/s1

SMILES Code: CC[C@H](C(O[C@@H]1[C@@H](c2c3c(C=CC(O3)=O)ccc2OC1(C)C)OC(C)=O)=O)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 388.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sparavigna A, Caputo A, Natoli A, Mandelli C. A randomized single-blind placebo-controlled study of a Visnadine Emulgel formulation on healthy postmenopausal women. Minerva Ginecol. 2019 Oct;71(5):353-358. doi: 10.23736/S0026-4784.19.04398-3. PMID: 31698889.


2: Durate J, Vallejo I, Pérez-Vizcaino F, Jiménez R, Zarzuelo A, Tamargo J. Effects of visnadine on rat isolated vascular smooth muscles. Planta Med. 1997 Jun;63(3):233-6. doi: 10.1055/s-2006-957660. PMID: 9225605.


3: Caputo A, Sparavigna A, Natoli A, Mandelli C. An open trial of a Visnadine emulgel topical application in postmenopausal superficial dyspareunia: daily vs. on-demand use. Minerva Ginecol. 2020 Feb;72(1):59-60. doi: 10.23736/S0026-4784.19.04402-2. Epub 2019 Sep 20. PMID: 31560182.


4: Bernorio R, Piloni S, Mori G, Prunas A, Bosoni D, Nappi RE. Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study. J Endocrinol Invest. 2018 Jun;41(6):729-737. doi: 10.1007/s40618-017-0801-0. Epub 2017 Dec 11. PMID: 29230716.


5: Caputo A, Natoli A, Radice R, Zanardi G, Giacomelli L. Efficacy of an intimate oil solution containing visnadine in women self-reporting sexual symptoms. Minerva Ginecol. 2018 Aug;70(4):492-493. doi: 10.23736/S0026-4784.18.04209-0. PMID: 29952501.


6: Caruso S, Mauro D, Cariola M, Fava V, Rapisarda AMC, Cianci A. Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder. Gynecol Endocrinol. 2018 Feb;34(2):110-114. doi: 10.1080/09513590.2017.1354366. Epub 2017 Jul 27. PMID: 28749253.


7: Laganà AS, Vitale SG, Stojanovska L, Lambrinoudaki I, Apostolopoulos V, Chiofalo B, Rizzo L, Basile F. Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy. Maturitas. 2018 Mar;109:78-80. doi: 10.1016/j.maturitas.2017.12.015. Epub 2017 Dec 24. PMID: 29452786.


8: Kiesewetter E. Koronartherapie mit Visnadin [Coronary treatment with visnadine]. Wien Med Wochenschr. 1969 May 3;119(18):346-7. German. PMID: 4979695.


9: Smith E, Pucci LA, Bywater WG. Crystalline Visnagan. Science. 1952 May 9;115(2993):520-1. doi: 10.1126/science.115.2993.520. PMID: 17809570.


10: TETREAU H. LA VISNADINE DANS LE TRAITEMENT DE L'INFARCTUS DU MYOCARDE ET DE LA MALADIE CORONARIENNE [VISNADINE IN THE TREATMENT OF MYOCARDIAL INFARCT AND CORONARY DISEASE]. Prog Med (Paris). 1964 Jul 10;92:485-94. French. PMID: 14182038.


11: Eyraud H, Aurousseau M. Study of the action of visnadine on general and cardiac hemodynamics. Arzneimittelforschung. 1973 Feb;23(2):201-7. PMID: 4739830.


12: Nkondi J, Bernard JP, Le Bars R, Cormier M, Paulet G. Nouvelle contribution à l'étude des effets biologiques de la visnadine [A further contribution to the study of biological effects of visnadine]. Therapie. 1966 Sep-Oct;21(5):1267-86. French. PMID: 5976773.


13: Erbing H, Uebel H, Vogel G. Zur Chemie, Pharmakologie und Toxikologie von Visnadin [On the chemistry, pharmacology and toxicology of Visnadine]. Arzneimittelforschung. 1967 Mar;17(3):283-7. German. PMID: 5631218.


14: Kukwa D. Klinische Beobachtungen zur Wirkung von Visnadin bei akuten Myocardschädigungen [Clinical observations on the effect of Visnadine in acute myocardial lesions]. Arzneimittelforschung. 1967 Mar;17(3):290-2. German. PMID: 5631220.


15: Hammerl H, Kränzl C, Pichler O, Studlar M. Untersuchungen über den Einfluss einer coronar wirksamen Substanz (Visnadin) auf den Fett-und Kohlenhydratstoffwechsel [Studies on the effect of the coronary active substance (Visnadine) on fat and carbohydrate metabolism]. Arzneimittelforschung. 1968 Mar;18(3):309-11. German. PMID: 5696005.


16: Bargheer R, Fiegel G, Saito S, Guttmann W. Die Wirkung von Visnadin bei chronisch-degenerativen Myocardschäden [The effect of Visnadine in chronic degenerative myocardial lesions]. Arzneimittelforschung. 1967 Mar;17(3):288-90. German. PMID: 5631219.


17: VARONOS DD, VOUKYDES PC, NIKITOPOULOU GC. Digitoxin antagonism by visnadin. J Pharm Sci. 1962 Oct;51:1013-4. doi: 10.1002/jps.2600511029. PMID: 13996356.


18: Bassino E, Antoniotti S, Gasparri F, Munaron L. Effects of flavonoid derivatives on human microvascular endothelial cells. Nat Prod Res. 2016 Dec;30(24):2831-2834. doi: 10.1080/14786419.2016.1154053. Epub 2016 Mar 2. PMID: 26936689.


19: Menghini L, Epifano F, Genovese S, Marcotullio MC, Sosa S, Tubaro A. Antiinflammatory activity of coumarins from Ligusticum lucidum Mill. subsp. cuneifolium (Guss.) Tammaro (Apiaceae). Phytother Res. 2010 Nov;24(11):1697-9. doi: 10.1002/ptr.3170. PMID: 21031631.


20: Winderl B, Schwaiger S, Ganzera M. Fast and improved separation of major coumarins in Ammi visnaga (L.) Lam. by supercritical fluid chromatography. J Sep Sci. 2016 Oct;39(20):4042-4048. doi: 10.1002/jssc.201600734. Epub 2016 Sep 8. PMID: 27514847.